SME logo


Success Story:

SMEs research lands EUR 50 million investment for revolutionary cancer treatment

Dr Titti Martinsson-Niskanen

The treatment of cancer is one of the most important areas of research in the medical world. A small research-based pharmaceutical company from Sweden has, together with its partner in Belgium, developed an innovative form of treatment that stops the growth of cancerous tumours through angiogenesis, the process by which new blood vessels are produced in the body. Three years on, the company has announced its results and secured a EUR 50 million investment from global pharmaceutical giant Roche.

The success

After three years of research, the collaboration produced some considerable results: there was a significant effect from the antibody in tumour models in mice, the toxicology study revealed it to be safe for human use, and BioInvent was able to produce enough antibody to enter into clinical studies.

The data compiled was so interesting and significant that the team was able to sell the results to Roche the global pharmaceutical giant for EUR 50 million, with the possibility of increasing this amount to EUR 450 million should the project reach certain development milestones.

'To go from being a small biotech company to selling our results to such a large industry player is fantastic,' explains a delighted Dr Niskanen. 'Its just a great testament to our work and has propelled us into the limelight across the medical world.'

Getting started
The programme
Why it worked